Pharma partner Presage acquires a clinical candidate of its own

Presage Biosciences, a popular partner for oncology drug developers, is wading into clinical development of its own, in-licensing a candidate and using its technology to spotlight potential combination therapies. The Seattle biotech acquired the rights to voruciclib, an oral CDK inhibitor, from India's Piramal Enterprises. Presage now plans to use its proprietary CIVO technology, which allows for the testing of cancer combinations on living tumors, to identify a path forward with the drug. To date, the company's development platform has helped it land agreements with Takeda and Celgene ($CELG). More

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.